ASCO 2025: Vepdegestrant could extend progression-free survival for some people with ESR1-mutated advanced breast cancer
Results from VERITAC-2, the first global phase 3 clinical trial of a PROTAC, a targeted…
Browsing: ASCO
ASCO 2025: Sacituzumab govitecan helps some patients with PD-L1-positive triple-negative breast cancer live longer without cancer progression
Results from an international phase 3 clinical trial show that treatment with sacituzumab govitecan and…
ASCO 2025: Molecular assay may help identify people with NSCLC who could benefit from adjuvant chemotherapy
Results from an international clinical trial show that a 14-gene molecular assay can help identify…
ASCO 2025: Post-hoc analysis demonstrates patient characteristics associated with long-term overall survival with irinotecan liposome injection in metastatic pancreatic adenocarcinoma
Late-breaking data from the Phase III NAPOLI 3 study were presented today at the 2025…
ASCO 2025: Pembrolizumab gives head and neck cancer patients extra years disease-free
An immunotherapy helps patients live years longer without their cancer getting worse or coming back,…
ASCO 2025: Adding nivolumab to chemoradiotherapy after surgery can decrease chance of recurrence in head and neck cancer
Results from the international phase 3 NIVOPOSTOP clinical trial found that adding nivolumab to chemoradiotherapy…
ASCO 2025: Pro-inflammatory diets associated with worse outcomes for stage III colon cancer
Results from a large, prospective cohort study show that eating a less inflammatory diet may…
ASCO 2025: Avelumab cetuximab combo improves PFS for for cutaneous squamous cell carcinoma
In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC),…
ASCO 2025: First phase 2 RCT of CAR T-cell therapy in solid tumours finds promising results
Patients with advanced gastric or gastro-oesophageal junction (GEJ) cancer treated with CAR T-cell therapy lived…
ASCO 2025: Artificial intelligence assistance can help improve accuracy in identifying HER2-low and HER2-ultralow breast cancers, avoid misclassification
Results from a multinational study found that using artificial intelligence (AI) assistance can help pathologists…